Video Library

Currently Viewing: Ted Lamson

NeoTract: Need, Solution, and Evidence Requirements

Ted Lamson, co-founder and CTO of NeoTract, shares his philosophy on the evidence requirements for a quality-of-life solution like the NeoTract offering.

Related Videos

•  5.3 Clinical Strategy •  NeoTract •  Ted Lamson • 

NeoTract: Proving Device Feasibility

Ted Lamson, co-founder and CTO of NeoTract, describes his approach to proving the feasibility of the company’s solution in humans before making a more substantial investment in development and testing.

Related Videos

•  5.3 Clinical Strategy •  NeoTract •  Ted Lamson • 

NeoTract: Choosing a Location and Investigators for Its First-in-Human Study

Ted Lamson, co-founder and CTO of NeoTract, outlines some of the key factors NeoTract considered in setting up its first-in-human study.

Related Videos

•  5.3 Clinical Strategy •  NeoTract •  Ted Lamson • 

NeoTract: Advantages of Conducting Early Studies Outside the U.S.

Ted Lamson, co-founder and CTO of NeoTract, comments on how it can sometimes be beneficial to conduct early clinical work outside the U.S.

Related Videos

•  5.3 Clinical Strategy •  NeoTract •  Ted Lamson • 

NeoTract: Early Study Design and Publication

Ted Lamson, co-founder and CTO of NeoTract, shares his experience and some pointer on clinical study design and devising a publication strategy.

Related Videos

•  5.3 Clinical Strategy •  NeoTract •  Ted Lamson • 

NeoTract: The Decision to Pursue a CE Mark

Ted Lamson, co-founder and CTO of NeoTract, explains why and when NeoTract decided to pursue a CE Mark.

Related Videos

•  5.4 Regulatory Strategy •  NeoTract •  Ted Lamson • 

NeoTract: CE Mark Experience

Ted Lamson, co-founder and CTO of NeoTract, describes how his company’s pursued a CE Mark.

Related Videos

•  5.4 Regulatory Strategy •  NeoTract •  Ted Lamson • 

NeoTract: Launching in Europe and Getting Value from Its CE Mark

Ted Lamson, co-founder and CTO of NeoTract, shares how and why his company undertook as selective European launch after receiving its CE Mark.

Related Videos

•  5.4 Regulatory Strategy •  NeoTract •  Ted Lamson • 

NeoTract: Preliminary Interactions with NICE

Ted Lamson, co-founder and CTO of NeoTract, explains when his company was approached by NICE and how it managed those interactions.

Related Videos

NeoTract: The NICE Decision and Its Impact

Ted Lamson, co-founder and CTO of NeoTract, discusses his technology’s initial NICE decision and the effect it has had on the company.

Related Videos

NeoTract: Pricing

Ted Lamson, co-founder and CTO of NeoTract, comments on pricing for medtech products.

Related Videos